Adoptive transfer cell therapies are a type of immunotherapy that attempts to train the patients intrinsic immune, resulting in cell-mediated responses on specific antigens to cure cancer.This type of immunotherapy is much more effective and is proved to have greater efficacy and less adverse reactions, as compared to traditional chemotherapy.Currently, there are 3 major types of cell immunotherapies in research or in the clinic: dendritic cell (DC) mediated, such as Provenge(R) (Dendreon/Valeant), the only US FDA approved cell-based specific active immunotherapy medicine; B lymphocyte (BC) mediated; and CAR-T technology.Although adoptive transfer cell immunotherapy is considered less toxic than chemotherapy, major and serious adverse effects (SAEs), such as cytokine release syndrome and virus infections are still existed in many clinical trials.This presentation tries to compare the major toxicities of these 3 types of adoptive transfer cell therapy and elucidates possibly mechanisms underlined these adverse effects.